Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHEEBA KOSHY THOMAS and HANS CHULHEE LEE.
SHEEBA KOSHY THOMAS
Connection Strength
2.133
HANS CHULHEE LEE
  1. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol. 2021 05; 193(3):e23-e26.
    View in: PubMed
    Score: 0.192
  2. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 2019 12; 94(12):E319-E322.
    View in: PubMed
    Score: 0.173
  3. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J. 2019 10 01; 9(10):80.
    View in: PubMed
    Score: 0.173
  4. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2024 Dec 31.
    View in: PubMed
    Score: 0.062
  5. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov 22.
    View in: PubMed
    Score: 0.062
  6. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 10 31; 14(1):189.
    View in: PubMed
    Score: 0.062
  7. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther. 2024 Aug; 30(8):772.e1-772.e11.
    View in: PubMed
    Score: 0.060
  8. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 05 17; 14(1):82.
    View in: PubMed
    Score: 0.060
  9. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 May; 204(5):1944-1952.
    View in: PubMed
    Score: 0.059
  10. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.
    View in: PubMed
    Score: 0.058
  11. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672.
    View in: PubMed
    Score: 0.058
  12. Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):193-199.
    View in: PubMed
    Score: 0.058
  13. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.
    View in: PubMed
    Score: 0.057
  14. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.
    View in: PubMed
    Score: 0.056
  15. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.
    View in: PubMed
    Score: 0.056
  16. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023 06 12; 41(6):1032-1047.e4.
    View in: PubMed
    Score: 0.056
  17. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.
    View in: PubMed
    Score: 0.054
  18. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.
    View in: PubMed
    Score: 0.053
  19. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
    View in: PubMed
    Score: 0.052
  20. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clin Cancer Res. 2022 04 01; 28(7):1277-1284.
    View in: PubMed
    Score: 0.051
  21. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8.
    View in: PubMed
    Score: 0.051
  22. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.
    View in: PubMed
    Score: 0.050
  23. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021 02 08; 11(2):17.
    View in: PubMed
    Score: 0.048
  24. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120.
    View in: PubMed
    Score: 0.047
  25. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma. 2020 11; 61(11):2763-2766.
    View in: PubMed
    Score: 0.045
  26. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.044
  27. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.
    View in: PubMed
    Score: 0.044
  28. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245.
    View in: PubMed
    Score: 0.043
  29. Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.
    View in: PubMed
    Score: 0.042
  30. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated? Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):e465-e469.
    View in: PubMed
    Score: 0.042
  31. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
    View in: PubMed
    Score: 0.042
  32. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74.
    View in: PubMed
    Score: 0.041
  33. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640.
    View in: PubMed
    Score: 0.041
  34. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.